Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.
Veringa A, Brüggemann RJ, Span LFR, Biemond BJ, de Boer MGJ, van den Heuvel ER, Klein SK, Kraemer D, Minnema MC, Prakken NHJ, Rijnders BJA, Swen JJ, Verweij PE, Wondergem MJ, Ypma PF, Blijlevens N, Kosterink JGW, van der Werf TS, Alffenaar JC; Voriconazole ZonMw Study Group. Veringa A, et al. Among authors: de boer mgj. Int J Antimicrob Agents. 2023 Feb;61(2):106711. doi: 10.1016/j.ijantimicag.2023.106711. Epub 2023 Jan 13. Int J Antimicrob Agents. 2023. PMID: 36642232 Free article. Clinical Trial.
Managing invasive aspergillosis in haematological patients in the era of resistance polymerase chain reaction and increasing triazole resistance: A modelling study of different strategies.
van de Peppel RJ, van der Beek MT, Visser LG, de Boer MGJ, Wallinga J. van de Peppel RJ, et al. Among authors: de boer mgj. Int J Antimicrob Agents. 2019 Mar;53(3):284-293. doi: 10.1016/j.ijantimicag.2018.10.021. Epub 2018 Nov 2. Int J Antimicrob Agents. 2019. PMID: 30395989
Effectiveness of oseltamivir in reduction of complications and 30-day mortality in severe seasonal influenza infection.
Groeneveld GH, Marbus SD, Ismail N, de Vries JJC, Schneeberger P, Oosterheert JJ, van Dissel JT, de Boer MGJ. Groeneveld GH, et al. Among authors: de vries jjc, de boer mgj. Int J Antimicrob Agents. 2020 Nov;56(5):106155. doi: 10.1016/j.ijantimicag.2020.106155. Epub 2020 Sep 6. Int J Antimicrob Agents. 2020. PMID: 32898685 Free article.
Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study.
Moes DJAR, van Westerloo DJ, Arend SM, Swen JJ, de Vries A, Guchelaar HJ, Joosten SA, de Boer MGJ, van Gelder T, van Paassen J. Moes DJAR, et al. Among authors: de vries a, de boer mgj. Clin Pharmacokinet. 2022 Feb;61(2):231-247. doi: 10.1007/s40262-021-01074-2. Epub 2021 Oct 11. Clin Pharmacokinet. 2022. PMID: 34633645 Free PMC article.
Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome.
van Grootveld R, Masarotto V, von dem Borne PA, Blijlevens NMA, Chitu DA, van der Beek MT, Fiocco M, de Boer MGJ. van Grootveld R, et al. Among authors: de boer mgj. BMC Infect Dis. 2023 Feb 6;23(1):78. doi: 10.1186/s12879-023-08013-5. BMC Infect Dis. 2023. PMID: 36747127 Free PMC article. Clinical Trial.
Implementation of a clinical decision rule for selecting empiric treatment for invasive aspergillosis in a setting with high triazole resistance.
van de Peppel RJ, van Grootveld R, Hendriks BJC, van Paassen J, Bernards S, Jolink H, Koopmans JG, von dem Borne PA, van der Beek MT, de Boer MGJ. van de Peppel RJ, et al. Among authors: de boer mgj. Med Mycol. 2021 Dec 8;60(1):myab060. doi: 10.1093/mmy/myab060. Med Mycol. 2021. PMID: 34878121 Free PMC article.
155 results